Dave Wilbur, MD, Pathologist, Medical Director of VisionGate Biosignatures Laboratory delivered a presentation at #ECC18, including how VisionGate’s Cell-CT ™ 3D Cytology Platform, AI, and the CellGazer™ software tool are delivering a new cancer diagnostic cytology capability

VisionGate is pleased to announce the appointment of Dr. James S. Burns to the Board of Directors. globenewswire.com/news-release/2…

VisionGate is pleased to announce the results and presentation of important new research at the IASLC World Conference on Lung Cancer, #WCLC2018. globenewswire.com/news-release/2…

Lung Cancer Screening Trial results were presented at the 2018 World Conference on Lung Cancer #WCLC2018. Trial Results Show Screening Significantly Reduces Lung Cancer Mortality Rates lungcanceralliance.org/blog/trial-res…

VisionGate Appoints R. John Glasspool as Chief Operating and Strategy Officer and member of the Board of Directors. globenewswire.com/news-release/2…

VisionGate Announces Lung Cancer Prevention Trial Progress and selects PCI Pharma Services as manufacturing partner for Oral Iloprost. Initial shipment of API has been achieved. #oncology, #lungcancer, #cancerresearch. globenewswire.com/news-release/2…

VisionGate Announces an Exclusive Global License, Manufacturing and Supply Agreement for Iloprost, VisionGate’s Phase 2 Oral Lung Cancer Interception Drug globenewswire.com/news-release/2…

VisionGate is attending ASCO and engaging with oncology leaders. Please contact us to meet for business engagement discussions on site.

youtube.com/watch?v=I9ttPp…

VG is attending the Precision Lung Cancer World R&D Summit in Boston July 25/26. To meet, contact us at 602.368.6132 visiongate3d.com

"visiongate Showcases Advances in Lung Cancer Early Detection and Treatment at the IASLC World Conference on Lung Cancer” globenewswire.com/news-release/2…

VisionGate is pleased to be attending the CHEST 2017 Meeting in Toronto Oct 29-Nov 1. We’ll be engaging with disease area experts and scheduling individual meetings w/ potential collaborators. Contact us to arrange a meeting by 602-368-6132 or visiongate3d.com

Much more must be done to eradicate lung cancer. VisionGate Inc. is developing new diagnostics & pharmaceuticals to improve early detection and treatment of lung cancer, bronchial dysplasia, pulmonary nodules, & patients at high risk for lung cancer. visiongate3d.com

New study: VisionGate’s evolving capability to perform true 3D imaging at the single cell level opens the door for new methods of early cancer detection. globenewswire.com/news-release/2…

VisionGate , Inc. is pleased to be attending the JP Morgan Healthcare Conference in San Francisco Jan 8-11. Please contact us to arrange a meeting time by calling 602-368-6132 or through our website at visiongate3d.com.

VisionGate is pleased to announce the appointment of Maria Forero and Paul Kelly to the Board of Directors, significantly expanding the depth of biotech leadership and business acumen within the company. globenewswire.com/news-release/2…

VisionGate is pleased to announce details on how the Company is leveraging the Cell-CT™ platform to expand Cancer Diagnostics Services, Biopharmaceutical Services and Cancer Prevention Medicines. globenewswire.com/news-release/2…

VisionGate to Present Late-Breaking Research at 2018 American Association of Cancer Research (AACR) Annual Meeting globenewswire.com/news-release/2…

@VisionGate3Dpresented a breakthrough research study at AACR demonstrating its Cell-CT™ platform can detect subtle changes in cellular and nuclear morphology of cancer-associated cells (CACs) as a result of the cancer field effect. globenewswire.com/news-release/2…

VisionGate, Inc. Appoints Randal Buness as Chief Financial Officer. “Randy Buness brings exceptional public company and IPO process experience to VisionGate, and we are pleased to have a seasoned strategic financial professional join our Executive Team" globenewswire.com/news-release/2…